Back to search
Drug Susceptible Pulmonary Tuberculosis
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Drug Susceptible Pulmonary Tuberculosis trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Drug Susceptible Pulmonary Tuberculosis trials you may qualify forThe purpose of this study is to evaluate if TBD09 in combination with other active agents in adults with drug sensitive pulmonary tuberculosis has potential to…
The purpose of this study is to determine if nicotinamide in combination with bedaquiline, pretomanid, and linezolid, is safe and effective in treating drug-sus…
While drug-susceptible tuberculosis (TB) disease in children currently requires four to six months of treatment, most children may be able to be cured with a sh…
Tuberculosis (TB) remains a major public health issue and one of the top ten causes of death from a single infectious disease worldwide. China is among the coun…
To determine if a high-dose first-line regimen is non-inferior (non-inferiority margin 10%) in terms of safety to the same regimen at regular dosing, in previou…
A multi-centre, randomized, open-label clinical trial. All treatments will be administered orally (PO) on days 1-14. 15 participants will be recruited into eac…
This is a phase 2, double-blind, randomized (1:1), placebo-controlled trial with two parallel groups. * H56:IC31 (investigational vaccine) * Placebo 900 HIV…
The PRESCIENT trial is a Phase IIc, open-label, randomized trial that will compare a 12-week regimen of bedaquiline (BDQ), clofazimine (CFZ), pyrazinamide (PZA)…
The study might come up with valuable findings to address poor treatment outcome, poor quality of life, disability score and depressive symptoms. The findings m…